Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants With Primary Hyperoxaluria Type 1 (PH1)

Next Previous
Trial Profile

A Phase 1/2 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ABO-101 in Participants With Primary Hyperoxaluria Type 1 (PH1)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABO 101 Arbor Biotechnologies (Primary)
  • Indications Hyperoxaluria
  • Focus Adverse reactions
  • Acronyms RedePHine
  • Sponsors Arbor Biotechnologies

Most Recent Events

  • 30 Jul 2025 According to an Arbor Biotechnologies media release, dose escalation ongoing with enrollment at Mayo Clinic in the US and plans to open additional sites in the UK and EU in Q3 of this year.
  • 30 Jul 2025 According to an Arbor Biotechnologies media release, first patient has been dosed in this trial.
  • 22 May 2025 Planned initiation date changed from 1 Apr 2025 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top